<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03298360</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS EP63 RESTA 32a</org_study_id>
    <nct_id>NCT03298360</nct_id>
  </id_info>
  <brief_title>A Chronological Study of the Formation of HIV Cellular Reservoirs Through the Expression of Surface Markers on CD4 + T Lymphocytes, Including CD32a</brief_title>
  <acronym>ANRS EP63</acronym>
  <official_title>A Chronological Study of the Formation of HIV Cellular Reservoirs Through the Expression of Surface Markers on CD4 + T Lymphocytes, Including CD32a</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To analyze the HIV viral sequences present in the CD32 + CD4a + T lymphocytes of the patients&#xD;
      who have participated in the ANRS 139 TRIO trial, always followed and in virological success,&#xD;
      and carrying multi-resistant viruses archived in the HIV cell reservoir, in order to&#xD;
      reconstruct the chronology of the installation of this reservoir.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives&#xD;
&#xD;
      Principal objective&#xD;
&#xD;
      To analyze the HIV viral sequences present in the CD32 + CD4a + T lymphocytes of the patients&#xD;
      who have participated in the ANRS 139 TRIO trial, always followed and in virological success,&#xD;
      and carrying multi-resistant viruses archived in the HIV cell reservoir, in order to&#xD;
      reconstruct the chronology of the installation of this reservoir.&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
      To analyze the HIV viral sequences present in the CD4 + lymphocytes with other membrane HIV&#xD;
      reservoir markers, currently being identified, in these same patients&#xD;
&#xD;
      Methodology&#xD;
&#xD;
      Pathophysiological study, in patients infected by multi drug-resistant viruses&#xD;
&#xD;
      Estimated enrollment&#xD;
&#xD;
      21 participants (total and per group)&#xD;
&#xD;
      Intervention&#xD;
&#xD;
      167mL blood sample in EDTA tube:&#xD;
&#xD;
        -  160mL (16 tubes of 10mL): for IGH (Institute of Human Genetics-Montpellier)&#xD;
&#xD;
        -  7mL (1tube of 7mL): to measure HIV-RNA in centers&#xD;
&#xD;
      Estimated planning or Study / Trial timetable&#xD;
&#xD;
      Study start date: September 2017&#xD;
&#xD;
      Enrollment period: 12 months&#xD;
&#xD;
      Total study duration: 24 months (analyses included)&#xD;
&#xD;
      Estimated study/trial completion date: September 2019 (one year after enrollment of the last&#xD;
      patient)&#xD;
&#xD;
      Study design&#xD;
&#xD;
      Cross-sectional survey, 167mL of blood in EDTA tube will be obtained on a research visit,&#xD;
      after signature of written informed consent&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2018</start_date>
  <completion_date type="Actual">June 25, 2020</completion_date>
  <primary_completion_date type="Actual">June 25, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of HIV viral sequences in the CD32 + CD4a + T lymphocytes of the patients</measure>
    <time_frame>inclusion</time_frame>
  </primary_outcome>
  <enrollment type="Actual">11</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>167mL of blood in EDTA tube will be obtained on a research visit, after signature of written informed consent</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HIV Infection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who participated to ANRS139 TRIO trial, and still followed in centers&#xD;
&#xD;
          -  Who remained in virological success since the participation at the trial: 90% of HIV-1&#xD;
             RNA level less than 50 copies/mL : one or more blips less than 1000 copies/mL are&#xD;
             tolerated&#xD;
&#xD;
          -  Genotypic resistance profiles available at baseline and before trial&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Affiliate or beneficiary of a social security system (the State Medical Aid or AME is&#xD;
             not a social security system).&#xD;
&#xD;
          -  Written informed consent signed by the person and the investigator before any exam&#xD;
             performed in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV-1 RNA level ≥ 1000 copies/mL at least once since the end of the 139 TRIO trial&#xD;
&#xD;
          -  Patient participating in another research evaluating other treatments with an&#xD;
             exclusion period ongoing at the screening visit.&#xD;
&#xD;
          -  Person under legal guardianship or deprived of liberty by a judicial or administrative&#xD;
             decision.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Monsef BENKIRANE</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 20, 2017</study_first_submitted>
  <study_first_submitted_qc>September 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2017</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV cell reservoir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

